Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Dermata Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 6 | 7 | +1 |
| Shares | 306.0K | 75.4K | −230.6K (−75.4%) |
| Value | $184.8K | $29.8K | −$155.0K (−83.9%) |
New holders (3)
Institutions that held Dermata Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 19,968 | $8.20K | 0.00% |
| Citadel Advisors LLC | 17,490 | $7.03K | 0.00% |
| Northwestern Mutual Wealth Management Co | 14 | $6 | 0.00% |
Sold out (2)
Institutions that held Dermata Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Armistice Capital, LLC | 218,000 | $133.0K |
| Virtu Financial LLC | 13,500 | $8.00K |